目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 74)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 STUDY SCOPE
1.4.1 MARKET SEGMENTATION
FIGURE 1 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: SEGMENTS COVERED
1.4.2 REGIONAL SEGMENTATION
FIGURE 2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 RESEARCH LIMITATIONS
1.7 SUMMARY OF CHANGES
1.7.1 RECESSION IMPACT

2 RESEARCH METHODOLOGY (Page No. - 80)
2.1 RESEARCH DATA
FIGURE 3 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
2.2 MARKET SIZE ESTIMATION
FIGURE 5 ACTIVE PHARMACEUTICAL INGREDIENT MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
2.2.1 GLOBAL MARKET ESTIMATION
FIGURE 6 MARKET SIZE ESTIMATION: APPaROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
FIGURE 7 ILLUSTRATIVE EXAMPLE OF PFIZER INC.: REVENUE SHARE ANALYSIS (2023)
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.3 MARKET GROWTH RATE PROJECTION
FIGURE 10 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: CAGR PROJECTIONS
2.3.1 IMPACT ANALYSIS OF DEMAND-SIDE AND SUPPLY-SIDE FACTORS
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.5 STUDY ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 IMPACT OF ECONOMIC RECESSION ON ACTIVE PHARMACEUTICAL INGREDIENT MARKET

3 EXECUTIVE SUMMARY (Page No. - 93)
FIGURE 12 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION)
FIGURE 13 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2024 VS. 2029 (USD BILLION)
FIGURE 14 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2024 VS. 2029 (USD BILLION)
FIGURE 15 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2024 VS. 2029 (USD BILLION)
FIGURE 16 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2023
FIGURE 17 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2024 VS. 2029 (USD BILLION)
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF ACTIVE PHARMACEUTICAL INGREDIENT MARKET

4 PREMIUM INSIGHTS (Page No. - 98)
4.1 ACTIVE PHARMACEUTICAL INGREDIENT MARKET OVERVIEW
FIGURE 19 INCREASING R&D FUNDING IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY TO DRIVE MARKET
4.2 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE AND COUNTRY, 2023
FIGURE 20 US AND INNOVATIVE APIS COMMANDED LARGEST MARKET SHARE IN 2023
4.3 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2024 VS. 2029
FIGURE 21 SYNTHETIC APIS TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2023
FIGURE 22 TRADITIONAL APIS POSSESSED LARGEST MARKET SHARE IN 2023
4.5 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 23 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD

5 MARKET OVERVIEW (Page No. - 101)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 24 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: IMPACT ANALYSIS
5.2.1 DRIVERS
5.2.1.1 Production capacity expansion in pharmaceutical & biopharmaceutical companies
5.2.1.2 Growing adoption of generic drugs
FIGURE 25 TOTAL SAVINGS FROM GENERIC DRUG USAGE IN US, 2013-2022 (USD BILLION)
TABLE 3 INDICATIVE LIST OF DRUGS GOING OFF-PATENT IN 2024
5.2.1.3 Increasing uptake of biopharmaceuticals
FIGURE 26 GLOBAL PHARMACEUTICAL R&D SPENDING, 2014-2028 (USD BILLION)
5.2.1.4 Technological advancements in API manufacturing
5.2.2 RESTRAINTS
5.2.2.1 Complications during API manufacturing
5.2.2.2 Low profit margin and high manufacturing cost
5.2.3 OPPORTUNITIES
5.2.3.1 Increased use of highly potent APIs
5.2.3.2 Potential growth opportunities in emerging economies
5.2.4 CHALLENGES
5.2.4.1 Rising penetration of counterfeit drugs
5.2.4.2 Stringent regulatory requirements for API manufacturing
5.2.5 TRENDS
5.2.5.1 Increased outsourcing to contract manufacturing organizations
5.2.5.2 Shift towards continuous processing
5.3 TECHNOLOGY ANALYSIS
5.3.1 KEY TECHNOLOGIES
5.3.1.1 Continuous manufacturing
5.3.1.2 Advanced analytical technique
5.3.1.3 Biocatalysis
5.3.2 COMPLIMENTARY TECHNOLOGIES
5.3.2.1 Data analytics and digitalization
5.3.2.2 Personalized medicine and custom synthesis
5.3.2.3 Supercritical fluid technology
5.3.3 ADJACENT TECHNOLOGIES
5.3.3.1 Supply chain visibility and blockchain
5.3.3.2 3D printing
5.3.3.3 Nanotechnology
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 27 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: SUPPLY CHAIN ANALYSIS
5.5 VALUE CHAIN ANALYSIS
FIGURE 28 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: VALUE CHAIN ANALYSIS
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY KEY PLAYER
TABLE 4 AVERAGE SELLING PRICE OF ACTIVE PHARMACEUTICAL INGREDIENTS, BY KEY PLAYER
5.7 ECOSYSTEM ANALYSIS
FIGURE 29 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ECOSYSTEM ANALYSIS
5.7.1 RAW MATERIAL SUPPLIERS
TABLE 5 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ROLE OF RAW MATERIAL SUPPLIERS IN ECOSYSTEM
5.7.2 INGREDIENT VENDORS
TABLE 6 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ROLE OF INGREDIENT VENDORS IN ECOSYSTEM
5.7.3 END USERS
TABLE 7 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ROLE OF END USERS IN ECOSYSTEM
5.7.4 REGULATORY BODIES
TABLE 8 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: ROLE OF REGULATORY BODIES IN ECOSYSTEM
5.8 PATENT ANALYSIS
5.8.1 METHODOLOGY
5.8.2 NUMBER OF PATENTS FILED
TABLE 9 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: NUMBER OF PATENTS FILED, 2014-2023
5.8.3 INNOVATION AND PATENT APPLICATIONS
FIGURE 30 TOTAL NUMBER OF PATENTS GRANTED FOR ACTIVE PHARMACEUTICAL INGREDIENTS, 2014-2023
5.8.4 TOP APPLICANTS
FIGURE 31 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014-2023
TABLE 10 TOP 20 PATENT OWNERS IN ACTIVE PHARMACEUTICAL INGREDIENT MARKET, 2014-2023
5.9 KEY CONFERENCES AND EVENTS, 2024-2025
TABLE 11 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: DETAILED LIST OF KEY CONFERENCES AND EVENTS, JANUARY 2024-DECEMBER 2025
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY SCENARIO
5.10.1.1 North America
5.10.1.1.1 US
5.10.1.1.2 Canada
5.10.1.2 Europe
5.10.1.2.1 Germany
5.10.1.2.2 UK
5.10.1.3 Asia Pacific
5.10.1.3.1 Japan
5.10.1.4 Latin America
5.10.1.4.1 Brazil
5.10.1.5 Middle East & Africa
5.10.1.5.1 Saudi Arabia
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 PORTER’S FIVE FORCES ANALYSIS
TABLE 17 ACTIVE PHARMACEUTICAL INGREDIENT MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ACTIVE PHARMACEUTICAL INGREDIENTS
5.12.2 KEY BUYING CRITERIA
FIGURE 33 KEY BUYING CRITERIA FOR END USERS
TABLE 18 KEY BUYING CRITERIA, BY END USER
5.13 INVESTMENT AND FUNDING SCENARIO
5.14 TRADE DATA
5.14.1 IMPORT DATA FOR ANTIBIOTICS (HS CODE: 2941)
TABLE 19 IMPORTERS FOR ANTIBIOTICS (HS CODE-2941)
5.14.2 EXPORT DATA FOR ANTIBIOTICS (HS CODE: 2941)
TABLE 20 EXPORTERS FOR ANTIBIOTICS (HS CODE-2941)
5.14.3 IMPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS (HS CODE: 2934)
TABLE 21 IMPORTERS FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) (HS CODE-2934)
5.14.4 EXPORT DATA FOR NUCLEIC ACIDS AND THEIR SALTS (HS CODE: 2934)
TABLE 22 EXPORTERS FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY) (HS CODE-2934)
5.14.5 IMPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES (HS CODE: 2937)
TABLE 23 IMPORTERS FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDES CHAIN MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE-2937)
5.14.6 EXPORT DATA FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES (HS CODE: 2937)
TABLE 24 EXPORTERS FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDES CHAIN MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE-2937)

6 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE (Page No. - 156)
6.1 INTRODUCTION
TABLE 25 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
6.2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE (CAPTIVE AND MERCHANT)
TABLE 26 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE (CAPTIVE AND MERCHANT), 2022-2029 (USD BILLION)
TABLE 27 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
6.3 INNOVATIVE APIS
6.3.1 INCREASING NUMBER OF REGULATORY APPROVALS FOR INNOVATIVE DRUGS TO BOOST MARKET GROWTH
TABLE 28 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY REGION, 2022-2029 (USD BILLION)
TABLE 29 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 30 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 31 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 32 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 33 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 34 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR INNOVATIVE APIS, BY COUNTRY, 2022-2029 (USD BILLION)
6.4 GENERIC APIS
6.4.1 INCREASED FOCUS ON GENERIC DRUGS AND LOW MANUFACTURING COSTS TO FUEL MARKET GROWTH
TABLE 35 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY REGION, 2022-2029 (USD BILLION)
TABLE 36 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 37 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 38 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 39 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 40 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 41 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR GENERIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)

7 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS (Page No. - 166)
7.1 INTRODUCTION
TABLE 42 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 (USD BILLION)
7.2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS (CAPTIVE AND MERCHANT)
TABLE 43 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS (CAPTIVE AND MERCHANT), 2022-2029 (USD BILLION)
TABLE 44 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 (USD BILLION)
7.3 SYNTHETIC APIS
TABLE 45 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY REGION, 2022-2029 (USD BILLION)
TABLE 46 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 47 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 48 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 49 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 50 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 51 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY COUNTRY, 2022-2029 (USD BILLION)
7.3.1 SYNTHETIC APIS MARKET, BY TYPE
TABLE 52 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
7.3.1.1 Innovative synthetic APIs
7.3.1.1.1 Innovative synthetic APIs to command larger market share during forecast period
TABLE 53 INNOVATIVE SYNTHETIC APIS MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 54 NORTH AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 55 EUROPE: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 56 ASIA PACIFIC: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 57 LATIN AMERICA: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 58 MIDDLE EAST: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 59 GCC COUNTRIES: INNOVATIVE SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.3.1.2 Generic synthetic APIs
7.3.1.2.1 Cost effectiveness and increased government support to fuel market growth
TABLE 60 GENERIC SYNTHETIC APIS MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 61 NORTH AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 62 EUROPE: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 63 ASIA PACIFIC: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 64 LATIN AMERICA: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 65 MIDDLE EAST: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 66 GCC COUNTRIES: GENERIC SYNTHETIC APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4 BIOTECH APIS
TABLE 67 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY REGION, 2022-2029 (USD BILLION)
TABLE 68 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 69 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 70 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 71 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 72 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 73 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.1 BIOTECH APIS MARKET, BY TYPE
TABLE 74 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
7.4.1.1 Innovative biotech APIs
7.4.1.1.1 Growing demand for innovative biopharmaceuticals to drive segment
TABLE 75 INNOVATIVE BIOTECH APIS MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 76 NORTH AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 77 EUROPE: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 78 ASIA PACIFIC: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 79 LATIN AMERICA: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 80 MIDDLE EAST: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 81 GCC COUNTRIES: INNOVATIVE BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.1.2 Generic biotech APIs
7.4.1.2.1 High demand for biosimilars to propel segment growth
TABLE 82 GENERIC BIOTECH APIS MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 83 NORTH AMERICA: GENERIC BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 84 EUROPE: GENERIC BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 85 ASIA PACIFIC: GENERIC BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 86 LATIN AMERICA: GENERIC BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 87 MIDDLE EAST: GENERIC BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 88 GCC COUNTRIES: GENERIC BIOTECH APIS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.2 BIOTECH APIS MARKET, BY PRODUCT
TABLE 89 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT 2022-2029 (USD BILLION)
7.4.2.1 Monoclonal antibodies
7.4.2.1.1 Growing applications of antibody-drug conjugates in cancer treatment to drive segment
TABLE 90 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 91 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 92 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 93 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 94 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 95 MIDDLE EAST: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 96 GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.2.2 Hormones & growth factors
7.4.2.2.1 Rising incidence of hormonal imbalance among geriatric and neonatal population to aid segment growth
TABLE 97 HORMONES & GROWTH FACTORS MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 98 NORTH AMERICA: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 99 EUROPE: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 100 ASIA PACIFIC: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 101 LATIN AMERICA: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 102 MIDDLE EAST: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 103 GCC COUNTRIES: HORMONES & GROWTH FACTORS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.2.3 Fusion proteins
7.4.2.3.1 Growing applications in biopharmaceuticals to augment segment growth
TABLE 104 FUSION PROTEINS MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 105 NORTH AMERICA: FUSION PROTEINS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 106 EUROPE: FUSION PROTEINS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 107 ASIA PACIFIC: FUSION PROTEINS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 108 LATIN AMERICA: FUSION PROTEINS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 109 MIDDLE EAST: FUSION PROTEINS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 110 GCC COUNTRIES: FUSION PROTEINS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.2.4 Cytokines
7.4.2.4.1 Effective use in regulating immune system, inflammation, and cell growth to augment segment growth
TABLE 111 CYTOKINES MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 112 NORTH AMERICA: CYTOKINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 113 EUROPE: CYTOKINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 114 ASIA PACIFIC: CYTOKINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 115 LATIN AMERICA: CYTOKINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 116 MIDDLE EAST: CYTOKINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 117 GCC COUNTRIES: CYTOKINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.2.5 Therapeutic enzymes
7.4.2.5.1 Growing use in cancer and pain management therapies to drive segment
TABLE 118 THERAPEUTIC ENZYMES MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 119 NORTH AMERICA: THERAPEUTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.3
TABLE 120 EUROPE: THERAPEUTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 121 ASIA PACIFIC: THERAPEUTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 122 LATIN AMERICA: THERAPEUTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 123 MIDDLE EAST: THERAPEUTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 124 GCC COUNTRIES: THERAPEUTIC ENZYMES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.3.1 Blood factors & anti-coagulants
7.4.3.1.1 Rising incidence of hemophilia to drive market
TABLE 125 BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 126 NORTH AMERICA: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 127 EUROPE: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 128 ASIA PACIFIC: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 129 LATIN AMERICA: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 130 MIDDLE EAST: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 131 GCC COUNTRIES: BLOOD FACTORS & ANTI-COAGULANTS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.3.2 Recombinant vaccines
7.4.3.2.1 Increasing funding for vaccine development to boost segment growth
TABLE 132 RECOMBINANT VACCINES MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 133 NORTH AMERICA: RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 134 EUROPE: RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 135 ASIA PACIFIC: RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 136 LATIN AMERICA: RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 137 MIDDLE EAST: RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 138 GCC COUNTRIES: RECOMBINANT VACCINES MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.4 BIOTECH APIS MARKET, BY EXPRESSION SYSTEM
TABLE 139 PHARMACEUTICAL INGREDIENTS MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
7.4.4.1 Mammalian expression systems
7.4.4.1.1 High expression level and easy scalability to propel segment growth
TABLE 140 MAMMALIAN EXPRESSION SYSTEMS MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 141 NORTH AMERICA: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 142 EUROPE: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 143 ASIA PACIFIC: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 144 LATIN AMERICA: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 145 MIDDLE EAST: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 146 GCC COUNTRIES: MAMMALIAN EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.4.2 Microbial expression systems
7.4.4.2.1 High expression levels of proteins at low costs to augment segment growth
TABLE 147 MICROBIAL EXPRESSION SYSTEMS MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 148 NORTH AMERICA: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 149 EUROPE: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 150 ASIA PACIFIC: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 151 LATIN AMERICA: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 152 MIDDLE EAST: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 153 GCC COUNTRIES: MICROBIAL EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.4.3 Yeast expression systems
7.4.4.3.1 Availability of efficient protein secretion and simple purification process to boost demand
TABLE 154 YEAST EXPRESSION SYSTEMS MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 155 NORTH AMERICA: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 156 EUROPE: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 157 ASIA PACIFIC: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 158 LATIN AMERICA: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 159 MIDDLE EAST: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 160 GCC COUNTRIES: YEAST EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.4.4 Insect expression systems
7.4.4.4.1 Effective post-translational modifications to boost segment growth
TABLE 161 INSECT EXPRESSION SYSTEMS MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 162 NORTH AMERICA: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 163 EUROPE: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 164 ASIA PACIFIC: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 165 LATIN AMERICA: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 166 MIDDLE EAST: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 167 GCC COUNTRIES: INSECT EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
7.4.4.5 Other expression systems
TABLE 168 OTHER EXPRESSION SYSTEMS MARKET, BY REGION, 2022-2029 (USD BILLION)
TABLE 169 NORTH AMERICA: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 170 EUROPE: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 171 ASIA PACIFIC: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 172 LATIN AMERICA: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 173 MIDDLE EAST: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 174 GCC COUNTRIES: OTHER EXPRESSION SYSTEMS MARKET, BY COUNTRY, 2022-2029 (USD BILLION)

8 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG (Page No. - 229)
8.1 INTRODUCTION
TABLE 175 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
8.2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG (CAPTIVE AND MERCHANT)
TABLE 176 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG (CAPTIVE AND MERCHANT), 2022-2029 (USD BILLION)
TABLE 177 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
8.3 PRESCRIPTION DRUGS
8.3.1 INCREASED ADOPTION OF SPECIALTY DRUGS TO SUPPORT MARKET GROWTH
TABLE 178 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY REGION, 2022-2029 (USD BILLION)
TABLE 179 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 180 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 181 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 182 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 183 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 184 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PRESCRIPTION DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
8.4 OVER-THE-COUNTER DRUGS
8.4.1 RISING PROMOTION OF SELF-MEDICATION TO PROPEL MARKET GROWTH
TABLE 185 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY REGION, 2022-2029 (USD BILLION)
TABLE 186 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 187 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 188 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 189 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 190 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 191 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OVER-THE-COUNTER DRUGS, BY COUNTRY, 2022-2029 (USD BILLION)

9 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY (Page No. - 239)
9.1 INTRODUCTION
TABLE 192 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
9.2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY (CAPTIVE AND MERCHANT)
TABLE 193 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY (CAPTIVE AND MERCHANT), 2022-2029 (USD BILLION)
TABLE 194 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
9.3 TRADITIONAL APIS
9.3.1 INCREASING NUMBER OF APPLICATIONS IN THERAPEUTIC AREAS TO SUPPORT MARKET GROWTH
TABLE 195 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY REGION, 2022-2029 (USD BILLION)
TABLE 196 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 197 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 198 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 199 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 200 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 201 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR TRADITIONAL APIS, BY COUNTRY, 2022-2029 (USD BILLION)
9.4 HIGHLY POTENT APIS
9.4.1 RISING PREVALENCE OF CANCER AND GROWING APPLICATIONS IN ONCOLOGY TO AID MARKET GROWTH
TABLE 202 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY REGION, 2022-2029 (USD BILLION)
TABLE 203 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 204 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 205 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 206 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 207 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 208 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR HIGHLY POTENT APIS, BY COUNTRY, 2022-2029 (USD BILLION)

10 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION (Page No. - 249)
10.1 INTRODUCTION
TABLE 209 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
10.2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT)
TABLE 210 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION (CAPTIVE AND MERCHANT), 2022-2029 (USD BILLION)
TABLE 211 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
10.3 COMMUNICABLE DISEASES
10.3.1 COMMUNICABLE DISEASES SEGMENT TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD
TABLE 212 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2022-2029 (USD BILLION)
TABLE 213 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 214 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 215 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 216 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 217 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 218 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
10.4 ONCOLOGY
10.4.1 INCREASING INCIDENCE OF CANCER AND RISING NUMBER OF FDA APPROVALS FOR ONCOLOGY DRUGS TO DRIVE MARKET
TABLE 219 LIST OF FDA-APPROVED DRUGS FOR DIFFERENT TYPES OF CANCER
TABLE 220 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY REGION, 2022-2029 (USD BILLION)
TABLE 221 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 222 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 223 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 224 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 225 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 226 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2029 (USD BILLION)
10.5 DIABETES
10.5.1 LARGE GERIATRIC POPULATION AND HIGH OBESITY RATES TO SUPPORT MARKET GROWTH
TABLE 227 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY REGION, 2022-2029 (USD BILLION)
TABLE 228 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 229 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 230 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 231 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 232 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 233 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR DIABETES, BY COUNTRY, 2022-2029 (USD BILLION)
10.6 CARDIOVASCULAR DISEASES
10.6.1 INCREASING INVESTMENT IN ADVANCED CARDIOVASCULAR THERAPIES TO AID MARKET GROWTH
TABLE 234 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2029 (USD BILLION)
TABLE 235 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 236 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 237 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 238 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 239 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 240 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
10.7 RESPIRATORY DISEASES
10.7.1 INCREASING POLLUTION LEVELS AND GROWING NUMBER OF COPD CASES TO FUEL MARKET GROWTH
TABLE 241 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISORDERS, 2022
TABLE 242 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY REGION, 2022-2029 (USD BILLION)
TABLE 243 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 244 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 245 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 246 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 247 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 248 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2022-2029 (USD BILLION)
10.8 PAIN MANAGEMENT
10.8.1 INCREASING DEMAND FOR ADVANCED PAIN MEDICATIONS TO PROPEL MARKET GROWTH
TABLE 249 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY REGION, 2022-2029 (USD BILLION)
TABLE 250 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 251 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 252 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 253 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 254 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 255 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2022-2029 (USD BILLION)
10.9 OTHER THERAPEUTIC APPLICATIONS
TABLE 256 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2022-2029 (USD BILLION)
TABLE 257 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 258 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 259 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 260 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 261 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 262 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022-2029 (USD BILLION)

11 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER (Page No. - 278)
11.1 INTRODUCTION
TABLE 263 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
11.2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER (CAPTIVE AND MERCHANT)
TABLE 264 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER (CAPTIVE AND MERCHANT), 2022-2029 (USD BILLION)
TABLE 265 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
11.3 PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY
11.3.1 INCREASING NUMBER OF COLLABORATIONS TO SUPPORT MARKET GROWTH
TABLE 266 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY REGION, 2022-2029 (USD BILLION)
TABLE 267 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 268 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 269 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 270 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 271 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 272 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY, BY COUNTRY, 2022-2029 (USD BILLION)
11.4 CONTRACT RESEARCH ORGANIZATIONS
11.4.1 INCREASING OUTSOURCING OF DRUG R&D ACTIVITIES TO SUPPORT MARKET GROWTH
TABLE 273 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022-2029 (USD BILLION)
TABLE 274 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 275 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 276 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 277 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 278 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 279 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
11.5 CONTRACT MANUFACTURING ORGANIZATIONS
11.5.1 INCREASED FOCUS ON BETTER QUALITY TO AID MARKET GROWTH
TABLE 280 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2022-2029 (USD BILLION)
TABLE 281 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 282 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 283 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 284 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 285 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 286 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2022-2029 (USD BILLION)
11.6 OTHER END USERS
TABLE 287 ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD BILLION)
TABLE 288 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 289 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 290 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 291 LATIN AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 292 MIDDLE EAST: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 293 GCC COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD BILLION)

12 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION (Page No. - 294)
12.1 INTRODUCTION
TABLE 294 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION, 2022-2029 (USD BILLION)
12.2 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION (CAPTIVE AND MERCHANT)
TABLE 295 ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION (CAPTIVE AND MERCHANT), 2022-2029 (USD BILLION)
TABLE 296 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY REGION, 2022-2029 (USD BILLION)
12.3 NORTH AMERICA
12.3.1 NORTH AMERICA: RECESSION IMPACT
FIGURE 34 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET SNAPSHOT
TABLE 297 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 298 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
TABLE 299 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
TABLE 300 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 301 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 302 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
TABLE 303 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
TABLE 304 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
TABLE 305 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
TABLE 306 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
TABLE 307 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
12.3.2 US
12.3.2.1 US to dominate North American active pharmaceutical ingredient market during study period
TABLE 308 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
TABLE 309 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
TABLE 310 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 311 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 312 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
TABLE 313 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
TABLE 314 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
TABLE 315 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
TABLE 316 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
TABLE 317 US: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
12.3.3 CANADA
12.3.3.1 Growing pharmaceutical manufacturing industry to support market growth
TABLE 318 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
TABLE 319 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
TABLE 320 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 321 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 322 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
TABLE 323 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
TABLE 324 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
TABLE 325 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
TABLE 326 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
TABLE 327 CANADA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
12.4 EUROPE
12.4.1 EUROPE: RECESSION IMPACT
TABLE 328 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 329 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
TABLE 330 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
TABLE 331 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 332 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 333 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
TABLE 334 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
TABLE 335 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
TABLE 336 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
TABLE 337 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
TABLE 338 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
12.4.2 GERMANY
12.4.2.1 High healthcare expenditure and advanced R&D facilities to drive market
TABLE 339 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
TABLE 340 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
TABLE 341 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 342 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 343 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
TABLE 344 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
TABLE 345 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
TABLE 346 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
TABLE 347 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
TABLE 348 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
12.4.3 UK
12.4.3.1 Rising government investments and growing focus on personalized treatment to drive market
TABLE 349 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
TABLE 350 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
TABLE 351 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 352 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 353 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
TABLE 354 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
TABLE 355 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
TABLE 356 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
TABLE 357 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
TABLE 358 UK: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
12.4.4 FRANCE
12.4.4.1 Increased focus on domestic API manufacturing to boost market growth
TABLE 359 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
TABLE 360 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
TABLE 361 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 362 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 363 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
TABLE 364 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
TABLE 365 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
TABLE 366 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
TABLE 367 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
TABLE 368 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
12.4.5 ITALY
12.4.5.1 Increasing investment in API production to fuel market growth
TABLE 369 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
TABLE 370 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
TABLE 371 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 372 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 373 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
TABLE 374 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
TABLE 375 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
TABLE 376 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
TABLE 377 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
TABLE 378 ITALY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
12.4.6 SPAIN
12.4.6.1 Increase in generic drug manufacturing capacity to propel market growth
TABLE 379 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
TABLE 380 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
TABLE 381 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 382 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 383 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
TABLE 384 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
TABLE 385 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
TABLE 386 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
TABLE 387 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
TABLE 388 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
12.4.7 HUNGARY
12.4.7.1 Increased focus on pharmaceutical manufacturing to drive market
TABLE 389 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
TABLE 390 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
TABLE 391 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 392 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 393 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
TABLE 394 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
TABLE 395 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
TABLE 396 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
TABLE 397 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
TABLE 398 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
12.4.8 REST OF EUROPE
TABLE 399 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
TABLE 400 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
TABLE 401 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 402 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 403 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
TABLE 404 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
TABLE 405 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
TABLE 406 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
TABLE 407 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
TABLE 408 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
12.5 ASIA PACIFIC
12.5.1 ASIA PACIFIC: RECESSION IMPACT
FIGURE 35 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET SNAPSHOT
TABLE 409 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY COUNTRY, 2022-2029 (USD BILLION)
TABLE 410 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
TABLE 411 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
TABLE 412 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 413 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 414 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
TABLE 415 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
TABLE 416 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
TABLE 417 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
TABLE 418 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
TABLE 419 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
12.5.2 JAPAN
12.5.2.1 Strong focus on drug innovation and improved R&D facilities to drive market
TABLE 420 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
TABLE 421 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
TABLE 422 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 423 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 424 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
TABLE 425 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
TABLE 426 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
TABLE 427 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
TABLE 428 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
TABLE 429 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
12.5.3 CHINA
12.5.3.1 High geriatric population and favorable government policies to support market growth
TABLE 430 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE, 2022-2029 (USD BILLION)
TABLE 431 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY SYNTHESIS, 2022-2029 USD BILLION)
TABLE 432 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR SYNTHETIC APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 433 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY TYPE, 2022-2029 (USD BILLION)
TABLE 434 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY PRODUCT, 2022-2029 (USD BILLION)
TABLE 435 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET FOR BIOTECH APIS, BY EXPRESSION SYSTEM, 2022-2029 (USD BILLION)
TABLE 436 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY TYPE OF DRUG, 2022-2029 (USD BILLION)
TABLE 437 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY POTENCY, 2022-2029 (USD BILLION)
TABLE 438 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY THERAPEUTIC APPLICATION, 2022-2029 (USD BILLION)
TABLE 439 CHINA: ACTIVE PHARMACEUTICAL INGREDIENT MARKET, BY END USER, 2022-2029 (USD BILLION)
12.5.4 INDIA
12.5.4.1 Increased demand f